胃癌细胞肿瘤坏死因子受体的研究

目的　探讨人胃癌细胞肿瘤坏死因子受体 ( TNFR)的数目与胃癌细胞分化程度以及与肿瘤坏死因子突变体 ( TNF- m)细胞毒效应之间的关系。方法　以12 5I- TNF- m为配体 ,用放射配体结合分析法 ,检测了高、中、低不同分化程度的体外培养胃癌细胞 ( MKN2 8、SGC790 1、MKN4 5)的 TNFR,同时用 MTT比色法研究了 TNF- m对三株胃癌细胞的细胞毒效应。结果　三株胃癌细胞 TNFR数目分别为每细胞 9.8× 10 -12 nmol、5.6× 10 -12 nmol、3.2× 10 -12 nmol,三者之间比较 ,TNFR数目差异有显著性 ( P<0 .0 5)。解离常数基本一致 ,同一温度时三株胃癌细胞 TNF- m的内化率几乎相等 ,且呈温度依赖关系。TNFR的半衰期大约为 90分钟 ,胞膜与胞浆 TNFR数目之比约为 1∶ 2 ,TNF- m对三株胃癌细胞的最大杀伤率分别为 86%、60 %、34 % ,差异有显著性 ( P<0 .0 5) ,且 39℃时的杀伤率高于37℃时的杀伤率。结论　胃癌细胞表面 TNFR数目与胃癌分化程度相关。 TNF- m的细胞毒效应与TNF数目及 TNF- m的内化量有关。     

喉癌中13号染色体杂合性丢失研究

目的　为初步限定喉癌中 13号染色体抑癌基因的缺失区域和为发现及定位抑癌基因提供线索和依据。方法　应用聚合酶链反应 ( PCR) ,筛查了 58例喉癌 (包括 3例原位癌 )组织中染色体13q上 D13S765( 13q13) ,RB1.2 0 ( 13q14.2 ) ,D13S133( 13q14.3) ,D13S318( 13q2 1) 4个座位微卫星多态标记的杂合性丢失。结果　 3例原位癌中无一例发生 13q的杂合性丢失 ,55例浸润癌中在 13q一个以上座位出现杂合性丢失的频率为 4 5% ( 2 4 / 53) ,D13S765座位的杂合性丢失的频率最高 ,为 52 %( 2 2 / 4 2 )。结论　喉癌组织中染色体 13q缺失区域在 D13S765( 13q13)座位附近 ,RB1的近端 ,即在D13S765座位附近存在着与喉癌发生发展密切相关的抑癌基因 ,可能包括 RB1基因 ,它的失活与浸润期喉癌发生发展密切相关。     

p53反义RNA对肠癌细胞恶性表型的抑制作用

研究ｐ５３反义ＲＮＡ对大肠癌细胞中突变型ｐ５３致癌性的抑制效应,为肿瘤基因治疗提供新思路。方法２．１ｋｂ的人ｐ５３全长ｃＤＮＡ反向插入哺乳动物表达载体ｐＲＥＰ９,得到ｐ５３反义ＲＮＡ表达载体ｐＲＥＰ９－ｐ５３（ＡＳ）,并将其导入人肠癌细胞株ＳＷ１１１６（内源性突变型ｐ５３）,采用ＭＴＴ和ＦＣＭ方法测定ｐＲＥＰ９－ｐ５３（ＡＳ）表达的ｐ５３反义ＲＮＡ对ＳＷ１１１６细胞生长的影响。结果带有ｐＲＥＰ９－ｐ５３（ＡＳ）的ＳＷ１１１６细胞,与对照组ＳＷ１１１６细胞和带ｐＲＥＰ９空载体的ＳＷ１１１６细胞相比,由于ｐ５３反义ＲＮＡ的表达,其增殖速度显著下降,ＦＣＭ的结果也证明带ｐＲＥＰ９－ｐ５３（ＡＳ）的细胞部分受阻于Ｇ０／１期,而带ｐＲＥＰ９空载体的细胞则无明显变化。结论ｐ５３反义ＲＮＡ可以有效地抑制大肠癌细胞中突变型ｐ５３的致癌性,可用于实验性肿瘤基因治疗研究     

A case of dermatofibrosarcoma protuberans in the skin over the breast

Dermatofibrosarcoma protuberans (DFSP) is a slow-growing but locally aggressive, fibrous tumor that has a high rate of local recurrence after surgical resection. This tumor occurs most commonly in the trunk and proximal extremities. In this report we present a case of dermatofibrosarcoma protuberans in the skin over the breast which was re-excised after pathological diagnosis, considering cosmetic aspects. Only three other cases of dermatofibrosarcoma protuberans of the anterior chest wall have been encountered in our hospital, and all of these cases were male. The presence of this tumor in the skin over the breast appears to be rare in females. Careful complete resection is recommended for this type of tumor.     

Angiosarcoma of the breast: Report of a case and autopsy findings

We report a case of angiosarcoma of the breast and the autopsy findings. The patient was a 35-year-old premenopausal woman who complained of a tumor in her left breast. We found a tumor measuring 55 mm in diameter in the lower external quadrant. The tumor was elastic and soft, smooth surfaced, well-defined and mobile. Dimpling sign or change of skin color were not observed. Clinically it was diagnosed as phyllodes tumor, but tumorectomy revealed primary angiosarcoma of the breast. Further extended surgery was recommended, but the patient refused additional therapy. Histological findings revealed a free surgical margin and neither lymph node metastasis nor distant metastasis were clinically observed. Seven months later, local recurrence in the same breast was recognized and finally radical mastectomy was carried out. Histological findings showed recurrence of angiosarcoma in the left breast but lymph node metastasis was not detected. Two months after mastectomy, metastases to the cervical and thoracic vertebrae were observed and radiation therapy was performed. Sixteen months from onset, she died due to multi-organ failure as general metastases of angiosarcoma. At autopsy, metastases to many organs including the digestive system were observed. The incidence of primary angiosarcoma of the breast is low but its prognosis is poor. This case emphasized the difficulties in clinical diagnosis and treatment for the angiosarcoma of the breast.     

Cytogenetic abnormalities related to histopathologic grade of astrocytic tumors

Cytogenetic analysis was performed on 7 lowgrade astrocytomas, 10 anaplastic astrocytomas, and 14 glioblastomas. Abnormal chromosome numbers were noted in all cases of high-grade astrocytomas but were rarely noted in low-grade astrocytomas (28%). The most consistent changes in high-grade astrocytomas were complete loss of chromosome 10 (61%), gain of chromosome 7 (56%), and loss of chromosome 17 (28%). Certain structural abnormalities, such as marker chromosomes and double minutes (33%), and the deletion and translocation of chromosomes 1 (33%) and 17 (17%), were also noted. These results indicate that changes in the number and/or structure of chromosomes with related inactivation of tumor suppressor gene or oncogene activation might play a critical role in the formation and anaplastic progression of astrocytic tumors.     

Intramedullary epidermoid cyst. A case report

The authors add to the literature a case report of a 32-year-old man with an intramedullary epidermoid cyst at the level of D 3/4, that was successfully operated on. There are several previous reports in the literature, but only five of these include MRI studies.     

Pharmacodynamics of Phenobarbital Anesthesia and Pentylenetetrazol-Induced Maximal Seizures in a Rat Model of Neoplastic Spinal Cord Compression

The purpose of this investigation was to determine whether paraplegia induced by neoplastic cord compression affects the pharmacodynamics of phenobarbital general anesthesia or of pentylenetet-razol (PTZ)-induced convulsions. Paraplegic rats harboring a thora-columbar epidural tumor, or an identical hindlimb tumor mass, received an i.v. infusion of phenobarbital until the onset of anesthesia. At that point, the phenobarbital concentrations in the CSF and serum were measured. Similarly, PTZ was infused until the onset of maximal seizures. It was found that changes related to systemic tumor growth and newly developed paraplegia due to neoplastic spinal cord compression did not attenuate the pharmacodynamics of phenobarbital. However, sustained paraplegia of 4 days duration reduced CNS sensitivity to the hypnotic action of the barbiturate as evidenced by the higher cerebrospinal fluid phenobarbital concentration required to induce anesthesia (170 ± 31 vs 125 ± 20 mg/L; P < 0.05). On the other hand, sustained paraplegia did not affect brain threshold concentration for PTZ-induced seizures.     

Selective incorporation of111In-labeled PHOTOFRIN™ by glioma tissuein vivo

The use of PHOTOFRIN for photodynamic therapy of human gliomas has been studied by i.v. administration and laser photosensitization. Defining the uptake of PHOTOFRIN in the patient's tumor in comparison with the surrounding normal brain tissue is highly desirable for patient selection and study ofin vivo kinetics. We utilized a non-invasive approach to the detection of PHOTOFRIN uptake in brain tumors with¹¹¹In-oxine radiolabeled PHOTOFRIN and external imaging and quantitation using a gamma camera. Biodistribution of¹¹¹In-labeled PHOTOFRIN in 13 organs was determined in four dogs and 15 mice with gliomas.^99mTc-DTPA was used as a control for nonspecific uptake. The greatest concentration of¹¹¹In-PHOTOFRIN in the brain tumor occurred at 24 hours post i.v. administration. The brain tumor PHOTOFRIN uptake was seven times greater than that of normal brain. The decreased blood background at 72 hours made this the optimum time for imaging. Specific tumor tissue uptake of¹¹¹In-PHOTOFRIN occurred, well beyond that resulting from blood-brain-barrier (BBB) breakdown.